Designed multiple ligands in metabolic disease research: From concept to platform

Drug Discovery Today

Volumn 18, Issue 15-16, 2013, Pages 692-696

  Gattrell, W ^a   Johnstone, C ^b   Patel, S ^c   Smith, C Sambrook ^d   Scheel, A ^b   Schindler, M ^e  

^a OXFORD PHARMAGENESIS LTD   (United Kingdom)

^b EVOTEC UK LTD   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Sygnature Discovery Limited   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DESIGNED MULTIPLE LIGAND; GLUCOSE; LEAD; LIGAND; SITAGLIPTIN; UNCLASSIFIED DRUG;

CRYSTAL STRUCTURE; GLUCOSE BLOOD LEVEL; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; MEDICAL RESEARCH; METABOLIC DISORDER; MOLECULAR BIOLOGY; NONHUMAN; REVIEW; SEQUENCE HOMOLOGY; VALIDATION PROCESS; X RAY CRYSTALLOGRAPHY;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DESIGN; HUMANS; LIGANDS; METABOLIC DISEASES;

EID: 84881173741     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.02.006     Document Type: Short Survey

References (26)

1. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
2. H.W. Rodbard Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr. Pract. 15 2009 540 559
3. S. Thayer Adherence to a fixed-dose combination of rosiglitazone/ glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea Ann. Pharmacother. 44 2010 791 799
4. T. Moulding Fixed-dose combinations of antituberculous medications to prevent drug resistance Ann. Intern. Med. 122 1995 951 954
5. L. Blonde, and Z.T. San Juan Fixed-dose combinations for treatment of type 2 diabetes mellitus Adv. Ther. 29 2012 1 13
6. S.E. Kahn Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N. Engl. J. Med. 355 2006 2427 2443 (Pubitemid 44903747)
7. R. Morphy From magic bullets to designed multiple ligands Drug Discov. Today 9 2004 641 651 (Pubitemid 38981718)
8. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 2008 682 690
9. L. Costantino, and D. Barlocco Designed multiple ligands: basic research vs clinical outcomes Curr. Med. Chem. 19 2012 3353 3387
10. R. Morphy, and Z. Rankovic The physicochemical challenges of designing multiple ligands J. Med. Chem. 49 2006 4961 4970 (Pubitemid 44201054)
11. Swain, S. et al. (2009) A Novel Dual DPP-IV Inhibitor and GPR119 Agonist that Exhibits Superior Glucose Lowering to Sitagliptin in Diabetic ZDF Rats. American Diabetes Association 69th Scientific Sessions, New Orleans, USA. June 5-9. Abstract 453-P. Available at: http://professional.diabetes.org/Abstracts- Display.aspx?TYP=1&CID=73240 Accessed February 2013
12. T. Ohishi, and S. Yoshida The therapeutic potential of GPR119 agonists for type 2 diabetes Expert Opin. Invest. Drugs 21 2012 321 328
13. H. Lan Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways Br. J. Pharmacol. 165 2012 2799 2807
14. Chu, Z-L. et al. Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level. US2006/0154866
15. Mark, M. et al. BoehringerIngelheim International Gmbh. Combination therapy for the treatment of diabetes and related conditions. US2011/0263617
16. G. Litwack Incretins and Insulin Secretion. Vitamins and Hormones vol. 84 2010 Elsevier
17. W.T. Gattrell An example of designed multiple ligands spanning protein classes: dual MCH-1R antagonists/DPPIV inhibitors Bioorg. Med. Chem. Lett. 22 2012 2464 2469
18. B. Kuhn Molecular recognition of ligands in dipeptidyl peptidase IV Curr. Top. Med. Chem. 7 2007 609 619 (Pubitemid 46488283)
19. Shah U, E.S., Szewczyk, J, (2012) Recent Advances in the Discovery of GPR119 Agonists. In New Therapeutic Strategies for Type 2 Diabetes (Jones., R., ed.), Chapter 7, pp. 177-214, The Royal Society of Chemistry
20. Barba, O. et al. Prosidion Ltd. 3-Substituted 5-(Pyrrolidine-1-carbonyl) Pyrrolidine and its derivatives for use in the treatment of metabolic disorders. WO2011128394
21. Barba, O. et al. Prosidion Ltd. Cycloamino derivatives as GPR119 agonists. WO2011147951
22. Barba, O. et al. Prosidion Ltd. 1,4-Disubstituted pyrrdolidine-3-yl-amine derivatives and their use for the treatment of metabolic disorders. WO2012066077
23. Barba, O. et al. Prosidion Ltd. N-Substituted 3-amino 4-(pyrrolidine-1-carbonyl)pyrrolidine and its derivatives for use in the treatment of metabolic disorders. WO2011128395
24. Barba, O. et al. Prosidion Ltd. Compounds for the treatment of metabolic disorders. WO2010103333
25. Barba, O. et al. Prosidion Ltd. Compounds for the treatment of metabolic disorders. WO2009034388
26. B.L. Roth Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discov. 3 2004 353 359 (Pubitemid 38499762)